National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

canarypox-hIL-12 melanoma vaccine
A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:ALVAC-hIL-12
ALVAC-hIL-12 melanoma vaccine



Previous:calcium gluconate, calusterone, Campath, Camptogen, Camptosar
Next:Cancidas, candesartan cilexetil, canertinib dihydrochloride, cannabis-based oromucosal spray GW-1000-02, Canvaxin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov